AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen
FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus.
AZN - AstraZeneca PLC
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Stock News
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
First Look: Ford EV pivot, AI infra slump, Uber suit
Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of AstraZeneca PLC (NASDAQ: AZN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the stock, MarketBeat reports. One analyst...
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Astrazeneca (AZN) closed the most recent trading day at $91.56, moving +1.93% from the previous trading session.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment...
Geneos Wealth Management Inc. Grows Stock Holdings in AstraZeneca PLC $AZN
Geneos Wealth Management Inc. boosted its holdings in AstraZeneca PLC (NASDAQ: AZN) by 329.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange...
AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Should You Sell?
AstraZeneca PLC (LON: AZN - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £117.76 and traded as high as...
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most...
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025
Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of...
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in...
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs...
AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers
FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.
Boston Partners Sells 46,721 Shares of AstraZeneca PLC $AZN
Boston Partners trimmed its stake in AstraZeneca PLC (NASDAQ: AZN) by 0.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange...
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications.
Aviso Financial Inc. Has $2.95 Million Position in AstraZeneca PLC $AZN
Aviso Financial Inc. lifted its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 5.6% in the second quarter, according to the company in its most recent filing with the Securities and...
Price Targets
AstraZeneca price target raised to $97 from $93 at Berenberg
$97.00
(was $70.82)
Luisa Hector
·
Berenberg Bank
AstraZeneca (AZN) PT Lowered to $88 at BMO Capital
$88.00
(was $81.19)
Etzer Darout
·
BMO Capital
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
$89.00
(was $79.94)
Etzer Darout
·
BMO Capital
AstraZeneca (AZN) PT Raised to $85 at Argus
$85.00
(was $76.84)
John Eade
·
Argus Research
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
$82.00
(was $76.74)
Etzer Darout
·
BMO Capital
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
$79.00
(was $64.86)
Andrew Berens
·
Leerink Partners
BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82
$82.00
(was $69.50)
BMO Capital
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78
$78.00
(was $65.09)
Leerink Partners
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75
$75.00
(was $67.17)
Leerink Partners